Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France

被引：0
|
作者：
Fily, A. Blom [1 ]
Mortier, L. [2 ]
Van Hille, B. [3 ]
Samimi, M. [4 ]
Luciani, L. [3 ]
Cahuzac, C. [3 ]
Robert, C. [5 ]
Quereux, G. [6 ]
Maubec, E. [7 ]
Maillard, C. [8 ]
Miotti, H. [8 ]
Aubin, F. [9 ,10 ]
Lenormand, C. [11 ]
Solbes, M-N. [3 ]
Modeste, A. B. Duval [12 ]
Kachaner, I. [13 ]
Lebbe, C. [14 ]
Dutriaux, C. [15 ]
Saiag, P. [1 ]
机构：
[1] CHU Ambroise Pare, Boulogne, France
[2] CHU Lille, Serv Dermatol, Hop Claude Huriez, Lille, France
[3] Merck Sante SAS, Lyon, France
[4] CHU Tours, Hop Trousseau, Tours, France
[5] Inst Gustave Roussy, Villejuif, France
[6] CHU Nantes, Hop Hotel Dieu, Nantes, France
[7] Hop Avicenne, APHP, Bobigny, France
[8] IQVIA Operat France, La Def, France
[9] CHU, Dermatol, Besancon, France
[10] Inserm 1098, Besancon, France
[11] Hop Univ Strasbourg, Serv Dermatol, Mcu Ph, Strasbourg, France
[12] CHU Rouen, Hop Charles Nicolle, Rouen, France
[13] Pfizer, Paris, France
[14] Univ Paris Cite, Dermatooncol, Hop St Louis, AP HP,CIC, Paris, France
[15] CHU Bordeaux, Hop St Andre, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1148P
引用
收藏
页码：S687 / S687
页数：1
相关论文
共 50 条
  • [21] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary
    Maraz, A. C.
    Nagy, B.
    Macher, T.
    Jesko, J.
    Tischler, E.
    Csongvai, C.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1341
  • [22] Frequency, characteristics, and subsequent treatment (Tx) of real-world patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC)
    Jalbert, Jessica J.
    Chen, Chieh-I
    Aguilar, Kathleen M.
    Davies, Kalatu
    LaFontaine, Patrick R.
    Fury, Matthew G.
    Bowler, Timothy
    Golozar, Asieh
    Cowey, C. Lance
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 233 - 234
  • [23] Frequency, characteristics, and subsequent treatment (Tx) of real-world patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC).
    Cowey, Charles Lance
    Chen, Chieh-I
    Aguilar, Kathleen M.
    Davies, Kalatu
    LaFontaine, Patrick R.
    Fury, Matthew G.
    Bowler, Timothy Geoffrey
    Golozar, Asieh
    Jalbert, Jessica J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).
    Amonkar, Mayur
    Gomez-Ulloa, David
    Kothari, Smita
    Cheung, Winson Y.
    Chau, Ian
    Zalcberg, John Raymond
    Lara, Nuria
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
    Choo, S. P.
    Mhatre, S. K.
    Ferro, A.
    Machado, R.
    Liu, D. H-C.
    Irahara, N.
    Gaillard, V. E.
    Shao, Y-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1309 - S1310
  • [26] Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
    Carson, K.
    Mahmoudpour, H.
    Ike, C.
    Monzon, S.
    Fragkogianni, S.
    Ferrer, J.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1216
  • [27] Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM)
    Carson, Kenneth Robert
    Ike, Chiemeka
    Mahmoudpour, Seyed Hamidreza
    Monzon, Sebastian
    Fragkogianni, Stamatina
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel
    Cowey, Charles Lance
    Liu, Frank X.
    Kim, Ruth
    Boyd, Marley
    Fulcher, Nicole
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    FUTURE ONCOLOGY, 2021, 17 (18) : 2339 - 2350
  • [29] Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
    D'Angelo, S. P.
    Nolte, S.
    Schlichting, M.
    Henry-Szatkowski, M.
    Hennessy, M.
    Bharmal, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 538 - 538
  • [30] Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapy
    Becker, J.
    Lorenz, E.
    Haas, G.
    Helwig, C.
    Oksen, D.
    Mahnke, L.
    Bharmal, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345